435 related articles for article (PubMed ID: 32605658)
21. Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.
Foggetti G; Ottaggio L; Russo D; Mazzitelli C; Monti P; Degan P; Miele M; Fronza G; Menichini P
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30745455
[TBL] [Abstract][Full Text] [Related]
22. Zn(II)-curc targets p53 in thyroid cancer cells.
Garufi A; D'Orazi V; Crispini A; D'Orazi G
Int J Oncol; 2015 Oct; 47(4):1241-8. PubMed ID: 26314369
[TBL] [Abstract][Full Text] [Related]
23. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
24. The Dual Roles of NRF2 in Cancer.
Menegon S; Columbano A; Giordano S
Trends Mol Med; 2016 Jul; 22(7):578-593. PubMed ID: 27263465
[TBL] [Abstract][Full Text] [Related]
25. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis.
Liu C; Rokavec M; Huang Z; Hermeking H
Cell Death Differ; 2023 Jul; 30(7):1771-1785. PubMed ID: 37210578
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling.
Iuchi K; Tasaki Y; Shirai S; Hisatomi H
Biomed Pharmacother; 2020 May; 125():109928. PubMed ID: 32004978
[TBL] [Abstract][Full Text] [Related]
27. The putative oncotarget CSN5 controls a transcription-uncorrelated p53-mediated autophagy implicated in cancer cell survival under curcumin treatment.
Zhang QY; Jin R; Zhang X; Sheng JP; Yu F; Tan RX; Pan Y; Huang JJ; Kong LD
Oncotarget; 2016 Oct; 7(43):69688-69702. PubMed ID: 27626169
[TBL] [Abstract][Full Text] [Related]
28. Arene-Ru(II) complexes of curcumin exert antitumor activity via proteasome inhibition and apoptosis induction.
Bonfili L; Pettinari R; Cuccioloni M; Cecarini V; Mozzicafreddo M; Angeletti M; Lupidi G; Marchetti F; Pettinari C; Eleuteri AM
ChemMedChem; 2012 Nov; 7(11):2010-20. PubMed ID: 22997162
[TBL] [Abstract][Full Text] [Related]
29. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.
Syu JP; Chi JT; Kung HN
Oncotarget; 2016 Mar; 7(12):14659-72. PubMed ID: 26894974
[TBL] [Abstract][Full Text] [Related]
30. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation.
Khor TO; Huang Y; Wu TY; Shu L; Lee J; Kong AN
Biochem Pharmacol; 2011 Nov; 82(9):1073-8. PubMed ID: 21787756
[TBL] [Abstract][Full Text] [Related]
32. Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231.
Meng C; Song L; Wang J; Li D; Liu Y; Cui X
Oncol Rep; 2017 Feb; 37(2):841-848. PubMed ID: 28035403
[TBL] [Abstract][Full Text] [Related]
33. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines.
Ebrahimi M; Babaei E; Neri F; Feizi MAH
Int J Pharm; 2021 May; 601():120592. PubMed ID: 33857585
[TBL] [Abstract][Full Text] [Related]
34. Nrf2 deficiency promotes apoptosis and impairs PAX7/MyoD expression in aging skeletal muscle cells.
Narasimhan M; Hong J; Atieno N; Muthusamy VR; Davidson CJ; Abu-Rmaileh N; Richardson RS; Gomes AV; Hoidal JR; Rajasekaran NS
Free Radic Biol Med; 2014 Jun; 71():402-414. PubMed ID: 24613379
[TBL] [Abstract][Full Text] [Related]
35. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1.
Na HK; Surh YJ
Free Radic Biol Med; 2014 Feb; 67():353-65. PubMed ID: 24200599
[TBL] [Abstract][Full Text] [Related]
37. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
38. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
39. NRF2 in Cancer: Cross-Talk with Oncogenic Pathways and Involvement in Gammaherpesvirus-Driven Carcinogenesis.
Cirone M; D'Orazi G
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614036
[TBL] [Abstract][Full Text] [Related]
40. Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte Necroptosis.
Lu C; Xu W; Zhang F; Shao J; Zheng S
Mol Pharm; 2016 Dec; 13(12):4043-4053. PubMed ID: 27764939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
